Celldex Hailed by Guggenheim After Positive Phase III Barzovolimab Data

Celldex Therapeutics (NASDAQ:CLDX) has emerged as a leading stock in Guggenheim's biotechnology sector rankings after the company reported highly positive topline results from two pivotal Phase III studies of its drug, barzovolimab.

Pivotal Trial Success

The investment firm's analysis highlighted the successful trials for barzovolimab in treating chronic spontaneous urticaria (CSU). According to Celldex, this represents the largest pivotal program ever conducted for CSU patients who are refractory to antihistamines, a group with significant unmet medical needs.

Guggenheim noted that results from both doses across both studies demonstrated a complete response that nearly aligned with the firm's bull-case scenario. This strong efficacy positions barzovolimab as a potential best-in-disease therapy for the condition.

Safety Profile and Program Setback

Ad

Guggenheim's analysis also addressed the drug's safety profile, noting that two cases of Grade 4 anaphylaxis across 2,400 patients represent an incidence rate of 0.08%, which the firm described as much lower than most approved drugs. The report pointed out that the Grade 4 designation was based on investigator discretion rather than an independent adjudication.

However, the positive CSU data contrasts with a recent setback for the same drug in a different indication. Celldex recently announced that its Phase II study of barzovolimab for prurigo nodularis failed to meet its primary endpoints, leading the company to discontinue that specific program.

Market Implications

The successful CSU trials address a significant market opportunity in patients who have not responded to existing treatments. The development has drawn mixed reactions from analysts following the full clinical update, with Morgan Stanley reportedly raising its price target on Celldex while Canaccord lowered its target.